Alzamend Neuro Inc (ALZN)

NASDAQ
Currency in USD
0.6800
-0.0206(-2.94%)
Closed·
After Hours
0.68000.0000(0.00%)
·
ALZN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.67500.7153
52 wk Range
0.642715.0600
Key Statistics
Edit
Prev. Close
0.7006
Open
0.681
Day's Range
0.675-0.7153
52 wk Range
0.6427-15.06
Volume
53.27K
Average Vol. (3m)
376.4K
1-Year Change
-90.29%
Book Value / Share
0.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALZN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.0000
Upside
+2,841.18%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Alzamend Neuro Inc Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Compare ALZN to Peers and Sector

Metrics to compare
ALZN
Peers
Sector
Relationship
P/E Ratio
−1.1x−3.5x−0.5x
PEG Ratio
−0.010.010.00
Price / Book
1.3x1.9x2.6x
Price / LTM Sales
-12.2x2.9x
Upside (Analyst Target)
-257.7%54.5%
Fair Value Upside
Unlock5.4%8.5%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 20.0000
(+2,841.18% Upside)

Earnings

Latest Release
Mar 10, 2025
EPS / Forecast
-0.19 / -0.60
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

0.063
AWHL
+73.97%
2.6850
SUNE
-9.90%
2.630
AMBO
+2.94%
4.230
SNOA
+9.59%
11.200
RDW
+2.10%

FAQ

What Is the Alzamend Neuro (ALZN) Stock Price Today?

The Alzamend Neuro stock price today is 0.68

What Stock Exchange Does Alzamend Neuro Trade On?

Alzamend Neuro is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Alzamend Neuro?

The stock symbol for Alzamend Neuro is "ALZN."

What Is the Alzamend Neuro Market Cap?

As of today, Alzamend Neuro market cap is 4.49M.

What is Alzamend Neuro Earnings Per Share?

The Alzamend Neuro EPS is -1.61.

From a Technical Analysis Perspective, Is ALZN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.